Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "SPI"

2986 News Found

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
News | March 18, 2026

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025


PsiQuantum joins forces with Japan’s National Cancer Center to revolutionize cancer research with quantum computing
R&D | March 18, 2026

PsiQuantum joins forces with Japan’s National Cancer Center to revolutionize cancer research with quantum computing

The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications


EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers
News | March 17, 2026

EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers

AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible


L&T Tech unveils AI-powered lung digital twin platform
Digitisation | March 17, 2026

L&T Tech unveils AI-powered lung digital twin platform

LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs


Johnson & Johnson reports promising early results for targeted bladder cancer therapy
Clinical Trials | March 17, 2026

Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors


QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system
News | March 16, 2026

QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system

The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise


GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
News | March 16, 2026

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk


Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler
R&D | March 16, 2026

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats


First patient dosed in trial of novel drug targeting limb-threatening artery disease
News | March 16, 2026

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts